Expanding the clinical spectrum of mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase deficiency with Turkish cases harboring novel HMGCS2 gene mutations and literature review. Issue 7 (7th April 2020)

• Record Type: Journal Article
• Authors: Kılıç, Mustafa; Dorum, Sevil; Topak, Ali; Yazıcı, Mutlu U.; Ezgu, Fatih S.; Coskun, Turgay
• Is Part Of: American journal of medical genetics. Volume 182:Issue 7(2020)
• Page Start: 1608
• Page End: 1614
• Publication Date: 2020-04-07
• Subjects: 3‐hydroxy‐3‐methylglutaryl‐CoA synthase deficiency -- encephalopathy -- HMG‐CoA synthase deficiency -- HMGCS2 -- hypoglycemia; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.61590
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract: Mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase (mHS) deficiency is a very rare autosomal recessive inborn error of ketone body synthesis and presents with hypoketotic hypoglycemia, metabolic acidosis, lethargy, encephalopathy, and hepatomegaly with fatty liver precipitated by catabolic stress. We report acute presentation of two patients from unrelated two families with novel homozygous c.862C>T and c.725‐2A>C mutations, respectively, in HMGCS2 gene. Affected patients had severe hypoketotic hypoglycemia, lethargy, encephalopathy, severe metabolic and lactic acidosis and hepatomegaly after infections. Surprisingly, molecular screening of the second family showed more affected patients without clinical findings. These cases expand the clinic spectrum of this extremely rare disease.